E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Classic Hodgkin Lymphoma Diffuse large B-cell lymphoma |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10020206 |
E.1.2 | Term | Hodgkin's disease |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10012818 |
E.1.2 | Term | Diffuse large B-cell lymphoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the antitumor activity of SAR444245 with or without other anticancer therapies |
|
E.2.2 | Secondary objectives of the trial |
- To confirm the dose and to assess the safety profile of SAR444245 when combined with or without other anticancer therapies. - To assess other indicators of antitumor activity. - To assess the plasma concentrations of SAR444245 when given with or without other anticancer therapies. - To assess the immunogenicity of SAR444245 |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
- Substudy 01 (cohort A): A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with pembrolizumab for the treatment of adults and adolescents with relapsed or refractory classic Hodgkin lymphoma - 16 July 2021, version 01 - See above for objectives
- Substudy 03 (cohort C1): A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) as monotherapy for the treatment of adults and adolescents with relapsed or refractory diffuse large B-cell lymphoma - 16 July 2021, version 01 - See above for objectives |
|
E.3 | Principal inclusion criteria |
- Participants must be ≥ 12 years of age, at the time of signing the informed consent - Disease location amenable to tumor biopsy at baseline - All participants must have a measurable disease - Females are eligible to participate if they are not pregnant or breastfeeding, not a woman of childbearing potential (WOCBP) or are a WOCBP that agrees: * to use approved contraception method and submit to regular pregnancy testing prior to treatment and for at least 180 days after discontinuing study treatment * and to refrain from donating or cryopreserving eggs for 180 days after discontinuing study treatment. - Males are eligible to participate if they agree to refrain from donating or cryopreserving sperm, and either abstain from heterosexual intercourse OR use approved contraception during study treatment and for at least 210 days after discontinuing study treatment. - Capable of giving signed informed consent
For cohort A (substudy 01): Histologically or cytologically confirmed diagnosis of cHL, must have received at least two prior lines of systemic therapy for cHL, including at least one containing an anthracycline or brentuximab.
For cohort C1 (substudy 03): Histologically or cytologically confirmed diagnosis of DLBCL, must have received at least two prior lines of systemic therapy for DLBCL, including at least one containing a combination of anthracycline and rituximab (or another anti-CD20 agent) with the last line of therapy a marketed CD19-directed CAR-T therapy. |
|
E.4 | Principal exclusion criteria |
- Eastern Cooperative Oncology Group (ECOG) performance status of ≥2 (≥ 16 years old). Lansky Scale (< 16 years old) < 50%. - Poor bone marrow reserve - Poor organ function - Participants with baseline SpO2 ≤92%. - Lymphomatous involvement of the central nervous system. - History of allogenic or solid organ transplant - Last administration of prior antitumor therapy or any investigational treatment within 21 days or less than 5 times the half-life, whichever is shorter; major surgery or local intervention within 21 days. - Has received prior IL-2-based anticancer treatment. - Comorbidity requiring corticosteroid therapy - Antibiotic use (excluding topical antibiotics) ≤14 days prior to first dose of IMP - Severe or unstable cardiac condition within 6 months prior to starting study treatment - Active, known, or suspected autoimmune disease that has required systemic treatment in the past 2 years - Known second malignancy either progressing or requiring active treatment within the last 3 years - Receipt of a live or live attenuated virus vaccination within 28 days of planned treatment start. Seasonal flu vaccines or SARS-CoV-2 vaccine that do not contain live virus are permitted. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Complete Response Rate for Cohort A: Complete response rate (CRR) defined as the proportion of participants who have a complete response (CR) determined by Investigator per Lugano response criteria 2014
Objective Response Rate for Cohort C1: Objective response rate (ORR) defined as the proportion of participants who have CR or partial response (PR) determined by the investigator per Lugano response criteria 2014 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline to the date of first documented progression or initiation of subsequent anticancer therapy or approximately 8 months after the last participant receive first dose |
|
E.5.2 | Secondary end point(s) |
1) To confirm the dose of SAR444245 when combined with or without other anticancer therapies: Incidence of Dose-limiting toxicities (DLTs) during DLT observation period 2) To assess the safety profile of SAR444245 when combined with or without other anticancer therapies: Incidence of treatment-emergent adverse events (TEAEs) and laboratory abnormalities according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V5.0 and American Society for Transplantation and Cellular Therapy (ASTCT) consensus gradings 3) To assess the safety profile of SAR444245 when combined with other anticancer therapies: Incidence of serious adverse events (SAEs) and laboratory abnormalities according to NCI CTCAE V5.0 and ASTCT consensus gradings 4) Objective Response Rate for Cohort A: Objective response rate (ORR) defined as the proportion of participants who have CR or partial response (PR) determined by Investigator per Lugano response criteria 2014 5) Time to Response (TTR): Time from the first administration of investigational medicinal product (IMP) to the first documented evidence of PR or CR determined by Investigator per Lugano response criteria 2014 6) Duration of Response: Duration of response (DoR) defined as the time from first documented evidence of CR or PR until progressive disease (PD) determined by Investigator per Lugano response criteria 2014, or death from any cause, whichever occurs first 7) Clinical Benefit Rate (CBR): CR or PR at any time or stable disease (SD) of at least 6 months (determined by Investigator per Lugano response criteria 2014) 8) Progression free survival: Progression free survival (PFS) defined as the time from the date of first IMP administration to the date of the first documented disease progression determined by Investigator per Lugano response criteria 2014 or death due to any cause, whichever occurs first 9) Complete Response Rate for Cohort C1: Complete response rate (CRR) defined as the proportion of participants who have a CR determined by Investigator per Lugano response criteria 2014 10) CAR-T cell activation and proliferation, suppression of circulating B cells for Cohort C1: CAR-T cell activation and proliferation, suppression of circulating B cells 11) To assess the plasma concentration of SAR444245 12) To assess incidence of anti-drug antibodies (ADAs) against SAR444245 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1) DLT Observation period for cohorts A and C1 is 21 days 2) From first IMP dose up to 30 days (30d) after last IMP dose 3) From first IMP dose up to 90d after last IMP dose 4,7,9,10) Baseline to the date of first documented progression or initiation of subsequent anticancer therapy or approx. 8 months after the last participant receive first dose 5,6,8) From the date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months 11) At Day 1 (D1) and D15 of Cycle 1, at D1 of Cycle 2-4-7-10 + every 5th cycle (each cycle is 21 days), max. is up to approx. 24 months 12) At D1 and D15 of Cycle1, at D1 of Cycle 2-4-7-10 + every 5th cycle and 30 days after last IMP administration, max. is up to approx. 24 months |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 18 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Canada |
Chile |
France |
Israel |
Italy |
Korea, Republic of |
Mexico |
Spain |
United Kingdom |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |